论文部分内容阅读
[目的]探讨乳腺癌患者外周血血小板膜糖蛋白CD62P、CD63水平变化的临床意义。[方法]采用流式细胞术检测40例健康人(正常对照组)和41例术前乳腺癌患者外周血血小板膜糖蛋白(CD62P、CD63)水平。[结果]乳腺癌患者外周血血小板膜糖蛋白水平(单纯血小板活化水平:CD62p2.04%±1.41%,CD631.64%±0.93%;黏附在细胞上的血小板活化水平:CD62p12.54%±8.35%,CD6318.27%±14.86%;外周血血小板总的活化水平:CD62p2.58%±1.69%,CD632.21%±1.24%)明显高于正常对照组(单纯血小板活化水平:CD62p1.04%±0.45%,CD630.64%±0.29%;黏附在细胞上的血小板活化水平:CD62p2.19%±0.85%,CD633.23%±1.64%;外周血血小板总的活化水平:CD62p1.48%±0.40%,CD631.29%±0.35%),差异有显著性(P<0.01)。乳腺癌患者CD62P、CD63水平变化分别受年龄、临床分期、手术与否及肿瘤有无转移等因素影响。[结论]外周血血小板膜糖蛋白水平可能成为监测乳腺癌患者病情进展的动态指标。
[Objective] To investigate the clinical significance of the changes of platelet membrane glycoprotein CD62P and CD63 in peripheral blood of breast cancer patients. [Methods] The levels of platelet membrane glycoprotein (CD62P, CD63) in 40 healthy volunteers (normal control group) and 41 preoperative breast cancer patients were detected by flow cytometry. [Results] The level of platelet membrane glycoprotein in peripheral blood of patients with breast cancer (platelet activation level: CD62p2.04% ± 1.41%, CD631.64% ± 0.93%; platelet adhesion activity on platelet activation: CD62p12.54% ± 8.35 %, CD6318.27% ± 14.86%; total peripheral blood platelet activation level: CD62p2.58% ± 1.69%, CD632.21% ± 1.24%) was significantly higher than the normal control group (platelet activation level: CD62p1.04% ± 0.45% and CD630.64% ± 0.29%, respectively. The levels of platelet adhesion on cells were: CD62p2.19% ± 0.85%, CD633.23% ± 1.64%; Total peripheral blood platelet activation level: CD62p1.48% ± 0.40%, CD631.29% ± 0.35%), the difference was significant (P <0.01). The changes of CD62P and CD63 levels in breast cancer patients were affected by factors such as age, clinical stage, operation or not, and tumor metastasis. [Conclusion] The level of peripheral blood platelet membrane glycoprotein may be the dynamic indicator to monitor the progression of breast cancer patients.